{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T08:54:24Z","timestamp":1764060864219,"version":"build-2065373602"},"reference-count":54,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1016\/j.clml.2019.03.027","type":"journal-article","created":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T11:18:44Z","timestamp":1554117524000},"page":"e489-e495","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Interferon Alpha Has a Strong Anti-tumor Effect in Philadelphia-negative Myeloproliferative Neoplasms"],"prefix":"10.1016","volume":"19","author":[{"given":"Patrizia","family":"Mondello","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristian","family":"Di Mirto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salvatore","family":"Cuzzocrea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmela","family":"Arrigo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Mian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincenzo","family":"Pitini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2019.03.027_bib1","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1001\/jama.1995.03530210078038","article-title":"Hematology: basic principles and practice","volume":"274","author":"Brunning","year":"1995","journal-title":"JAMA"},{"key":"10.1016\/j.clml.2019.03.027_bib2","doi-asserted-by":"crossref","first-page":"e123","DOI":"10.1182\/blood-2014-02-554634","article-title":"Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis","volume":"123","author":"Rampal","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.03.027_bib3","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1038\/sj.leu.2404810","article-title":"Prevalence and clinicopathologic correlates of JAK2 exon 12 mutations in JAK2V617F-negative polycythemia vera","volume":"21","author":"Pardanani","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2019.03.027_bib4","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1038\/leu.2008.113","article-title":"Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal","volume":"22","author":"Vannucchi","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2019.03.027_bib5","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1182\/blood-2014-05-579136","article-title":"Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis","volume":"124","author":"Tefferi","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.03.027_bib6","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41408-017-0042-7","article-title":"Polycythemia vera treatment algorithm 2018","volume":"8","author":"Tefferi","year":"2018","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2019.03.027_bib7","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1038\/s41408-017-0041-8","article-title":"Essential thrombocythemia treatment algorithm 2018","volume":"8","author":"Tefferi","year":"2018","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2019.03.027_bib8","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1038\/s41408-018-0109-0","article-title":"Myelofibrosis treatment algorithm 2018","volume":"8","author":"Tefferi","year":"2018","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2019.03.027_bib9","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1586\/17474086.2016.1154452","article-title":"Alleviating anemia and thrombocytopenia in myelofibrosis patients","volume":"9","author":"Cervantes","year":"2016","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.clml.2019.03.027_bib10","doi-asserted-by":"crossref","first-page":"121","DOI":"10.3109\/10428194.2013.794269","article-title":"Splenectomy in patients with myeloproliferative neoplasms: efficacy, complications and impact on survival and transformation","volume":"55","author":"Santos","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2019.03.027_bib11","doi-asserted-by":"crossref","first-page":"5394","DOI":"10.1182\/blood-2009-02-195974","article-title":"How I treat symptomatic splenomegaly in patients with myelofibrosis","volume":"113","author":"Mesa","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.03.027_bib12","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1182\/blood.V95.7.2226","article-title":"Splenectomy in myelofibrosis with myeloid metaplasia: a single-institution experience with 223 patients","volume":"95","author":"Tefferi","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.03.027_bib13","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1110557","article-title":"A\u00a0double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis","volume":"366","author":"Verstovsek","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2019.03.027_bib14","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1056\/NEJMoa1110556","article-title":"JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis","volume":"366","author":"Harrison","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2019.03.027_bib15","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1056\/NEJMoa1409002","article-title":"Ruxolitinib versus standard therapy for the treatment of polycythemia vera","volume":"372","author":"Vannucchi","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2019.03.027_bib16","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/S1470-2045(16)30558-7","article-title":"Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study","volume":"18","author":"Passamonti","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2019.03.027_bib17","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.bbmt.2009.10.025","article-title":"Outcome of transplantation for myelofibrosis","volume":"16","author":"Ballen","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clml.2019.03.027_bib18","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.bbmt.2006.11.004","article-title":"Hematopoietic cell transplantation as curative therapy for idiopathic myelofibrosis, advanced polycythemia vera, and essential thrombocythemia","volume":"13","author":"Kerbauy","year":"2007","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clml.2019.03.027_bib19","doi-asserted-by":"crossref","first-page":"3912","DOI":"10.1182\/blood-2003-06-1856","article-title":"Allogeneic hematopoietic stem cell transplantation for myelofibrosis","volume":"102","author":"Deeg","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.03.027_bib20","doi-asserted-by":"crossref","first-page":"3370","DOI":"10.1182\/blood.V90.9.3370","article-title":"Treatment of polycythemia vera: the use of hydroxyurea and pipobroman in 292 patients under the age of 65 years","volume":"90","author":"Najean","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.03.027_bib21","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1111\/j.1600-0609.1994.tb01303.x","article-title":"Acute leukaemia after hydroxyurea therapy in polycythaemia vera and allied disorders: prospective study of efficacy and leukaemogenicity with therapeutic implications","volume":"52","author":"Weinfeld","year":"1994","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clml.2019.03.027_bib22","first-page":"24","article-title":"Management of polycythemia vera with hydroxyurea","volume":"34","author":"Tatarsky","year":"1997","journal-title":"Semin Hematol"},{"key":"10.1016\/j.clml.2019.03.027_bib23","doi-asserted-by":"crossref","first-page":"3065","DOI":"10.1182\/blood-2008-03-143537","article-title":"Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera","volume":"112","author":"Kiladjian","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.03.027_bib24","doi-asserted-by":"crossref","first-page":"5418","DOI":"10.1200\/JCO.2009.23.6075","article-title":"Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera","volume":"27","author":"Quint\u00e1s-Cardama","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2019.03.027_bib25","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.6004\/jnccn.2016.0133","article-title":"Practice patterns in the diagnosis and treatment of polycythemia vera in the post-JAK2 V617F discovery era","volume":"14","author":"Kander","year":"2016","journal-title":"J\u00a0Natl Compr Canc Netw"},{"key":"10.1016\/j.clml.2019.03.027_bib26","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1007\/s00432-016-2209-1","article-title":"Characteristics and treatment of polycythemia vera patients in clinical practice: a multicenter chart review on 1476 individuals in Germany","volume":"142","author":"Jentsch-Ullrich","year":"2016","journal-title":"J\u00a0Cancer Res Clin Oncol"},{"key":"10.1016\/j.clml.2019.03.027_bib27","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/S1074-7613(01)00154-6","article-title":"Interferons alpha and beta as immune regulators--a new look","volume":"14","author":"Biron","year":"2001","journal-title":"Immunity"},{"key":"10.1016\/j.clml.2019.03.027_bib28","doi-asserted-by":"crossref","first-page":"204","DOI":"10.3109\/08916930903510880","article-title":"Recent advances on the immunomodulatory effects of IFN-\u03b1: implications for cancer immunotherapy and autoimmunity","volume":"43","author":"Rizza","year":"2010","journal-title":"Autoimmunity"},{"key":"10.1016\/j.clml.2019.03.027_bib29","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1182\/blood.V88.7.2450.bloodjournal8872450","article-title":"Targeted T-cell therapy for human leukemia: cytotoxic T lymphocytes specific for a peptide derived from proteinase 3 preferentially lyse human myeloid leukemia cells","volume":"88","author":"Molldrem","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.03.027_bib30","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/S1074-7613(01)00126-1","article-title":"Type I interferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in\u00a0vivo","volume":"14","author":"Le Bon","year":"2001","journal-title":"Immunity"},{"key":"10.1016\/j.clml.2019.03.027_bib31","doi-asserted-by":"crossref","first-page":"4907","DOI":"10.4049\/jimmunol.177.7.4907","article-title":"An unconventional antigen translated by a novel internal ribosome entry site elicits antitumor humoral immune reactions","volume":"177","author":"Xiong","year":"2006","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.clml.2019.03.027_bib32","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1056\/NEJMoa1311347","article-title":"Somatic mutations of calreticulin in myeloproliferative neoplasms","volume":"369","author":"Klampfl","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2019.03.027_bib33","doi-asserted-by":"crossref","first-page":"3212","DOI":"10.1182\/blood-2014-07-551929","article-title":"How I treat polycythemia vera","volume":"124","author":"Vannucchi","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.03.027_bib34","doi-asserted-by":"crossref","first-page":"4778","DOI":"10.1182\/blood-2013-01-478891","article-title":"Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project","volume":"121","author":"Barosi","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.03.027_bib35","doi-asserted-by":"crossref","first-page":"e165","DOI":"10.1016\/S2352-3026(17)30030-3","article-title":"Pegylated interferon alfa-2a in patients with essential thrombocythaemia or polycythaemia vera: a post-hoc, median 83 month follow-up of an open-label, phase 2 trial","volume":"4","author":"Masarova","year":"2017","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.clml.2019.03.027_bib36","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1182\/blood-2012-07-442012","article-title":"Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon-2a","volume":"122","author":"Quint\u00e1s-Cardama","year":"2013","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1016\/j.clml.2019.03.027_bib37","first-page":"320","article-title":"Ropeginterferon alfa-2b induces high rates of clinical, hematological and molecular responses in polycythemia vera: two-year results from the first prospective randomized controlled trial","volume":"130","author":"Gisslinger","year":"2017","journal-title":"Blood"},{"author":"Gisslinger","key":"10.1016\/j.clml.2019.03.027_bib38"},{"key":"10.1016\/j.clml.2019.03.027_bib39","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1182\/blood.V128.22.479.479","article-title":"Interim analysis of the Myeloproliferative Disorders Research Consortium (MPD-RC) 112 global phase III trial of front line pegylated interferon alpha-2a vs. hydroxyurea in high risk polycythemia vera and essential thrombocythemia","volume":"128","author":"Mascarenhas","year":"2016","journal-title":"Blood"},{"author":"Knudsen","key":"10.1016\/j.clml.2019.03.027_bib40"},{"key":"10.1016\/j.clml.2019.03.027_bib41","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1038\/leu.2010.120","article-title":"Clonal analysis of erythroid progenitors suggests that pegylated interferon alpha-2a treatment targets JAK2V617F clones without affecting TET2 mutant cells","volume":"24","author":"Kiladjian","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2019.03.027_bib42","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1182\/blood-2015-07-659060","article-title":"Clinical and molecular response to interferon- therapy in essential thrombocythemia patients with CALR mutations","volume":"126","author":"Verger","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.03.027_bib43","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1023\/A:1023668705040","article-title":"Apoptosis and interferons: role of interferon-stimulated genes as mediators of apoptosis","volume":"8","author":"Chawla-Sarkar","year":"2003","journal-title":"Apoptosis"},{"key":"10.1016\/j.clml.2019.03.027_bib44","doi-asserted-by":"crossref","first-page":"244","DOI":"10.3109\/08916930903510963","article-title":"Interferon-alpha as angiogenesis inhibitor: learning from tumor models","volume":"43","author":"Indraccolo","year":"2010","journal-title":"Autoimmunity"},{"key":"10.1016\/j.clml.2019.03.027_bib45","doi-asserted-by":"crossref","first-page":"2627","DOI":"10.1200\/JCO.1996.14.10.2627","article-title":"Interferons as biochemical modulators","volume":"14","author":"Borden","year":"1996","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2019.03.027_bib46","doi-asserted-by":"crossref","first-page":"28570","DOI":"10.1074\/jbc.M011685200","article-title":"The p38 MAPK pathway mediates the growth inhibitory effects of interferon-alpha in BCR-ABL-expressing cells","volume":"276","author":"Mayer","year":"2001","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.clml.2019.03.027_bib47","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1038\/leu.2013.163","article-title":"Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study","volume":"27","author":"Tefferi","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2019.03.027_bib48","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1200\/JCO.2011.34.7542","article-title":"Treatment-related risk factors for transformation to acute myeloid leukemia and myelodysplastic syndromes in myeloproliferative neoplasms","volume":"29","author":"Bj\u00f6rkholm","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2019.03.027_bib49","doi-asserted-by":"crossref","first-page":"479","DOI":"10.3324\/haematol.2014.115840","article-title":"Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I","volume":"100","author":"Verstovsek","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2019.03.027_bib50","doi-asserted-by":"crossref","first-page":"4047","DOI":"10.1182\/blood-2013-02-485888","article-title":"Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis","volume":"122","author":"Cervantes","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.03.027_bib51","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1182\/blood-2015-03-635235","article-title":"The effect of long-term ruxolitinib treatment on JAK2p.V617F allele burden in patients with myelofibrosis","volume":"126","author":"Deininger","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.03.027_bib52","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1002\/cncr.21900","article-title":"A\u00a0phase II trial of pegylated interferon \u03b1-2b therapy for polycythemia vera and essential thrombocythemia","volume":"106","author":"Samuelsson","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2019.03.027_bib53","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1007\/s00277-008-0498-4","article-title":"Sustained major molecular response on interferon alpha-2b in two patients with polycythemia vera","volume":"87","author":"Larsen","year":"2008","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2019.03.027_bib54","doi-asserted-by":"crossref","first-page":"3571","DOI":"10.1002\/cam4.1619","article-title":"Safety and efficacy of combination therapy of interferon-\u03b12 and ruxolitinib in polycythemia vera and myelofibrosis","volume":"7","author":"Mikkelsen","year":"2018","journal-title":"Cancer Med"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265019300874?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265019300874?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:32:13Z","timestamp":1761870733000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265019300874"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":54,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["S2152265019300874"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2019.03.027","relation":{},"ISSN":["2152-2650"],"issn-type":[{"type":"print","value":"2152-2650"}],"subject":[],"published":{"date-parts":[[2019,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Interferon Alpha Has a Strong Anti-tumor Effect in Philadelphia-negative Myeloproliferative Neoplasms","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2019.03.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}